Junctional and Dystrophic Epidermolysis Bullosa by Daisuke Tsuruta et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books










© 2013 Tsuruta et al., licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Junctional and Dystrophic Epidermolysis Bullosa 
Daisuke Tsuruta, Chiharu Tateishi and Masamitsu Ishii 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/54610 
1. Introduction 
Epidermolysis bullosa (EB) is a congenital genodermatosis, which affects mainly skin and 
occasionally other organs [1]. Lifelong blistering and erosion of the skin and mucous 
membrane, caused by mechanical trauma, threaten EB patients [1]. The most common cause 
of death is metastasizing squamous cell carcinoma [2]. EB is subdivided into mainly three 
categories by the location of tissue separation (blister) in the basement membrane zone 
(BMZ) at the electronmicroscopical level, EB simplex (EBS), dystrophic EB (DEB) and 
junctional EB (JEB)[1]. Some dermatologists also proposed to distinguish hemidesmosomal 
epidermolysis bullosa [3]. In EBS, blister locates at the level of basal keratinocytes, in DEB at 
the level of lamina lucida and in DEB at the level of the dermis [1]. EB is mainly caused by 
the mutation of keratin filament, hemidesmosome components or collagen genes [1]. Thus 
far, at least 10 different genes are identified as causative genes for EB [1,4,5]. 
2. The molecular components of BMZ (Figure 1) 
The keratin is the most abundant structural proteins found in epithelial cells [6]. The 
keratins are polymers of type I and type II intermediate filaments [6]. In basal keratinocytes, 
type I intermediate filament is keratin 14 (K14) and type II intermediate filament is keratin 5 
(K5)[6]. These two types of keratins are the major mutated molecules found in EBS [6]. 
Hemidesmosomes are very tight cell-matrix junction structures which connect basal 
keratinocytes to the basement membrane [7]. Hemidesmosomes tether keratin filaments to 
the cell surface [7]. Ultrastructurally, hemidemosomes comprises the inner plaques, the 
outer plaques, anchoring fibrils and anchoring filaments [8]. At the molecular level, core of 
each hemidesmosome comprises of four transmembrane proteins, 180 kDa-bullous 
pemphigoid antigen (BP180, type XVII collagen, BPAG2),  integrins and CD151 
tetraspanin protein [7]. Both BP180 and  integrin interacts with laminin-332 at the BMZ  
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Figure 1. Molecular components of basement membrane zone. 
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Figure 2. Clinical (left) and electronmicroscopical (right) appearances of dystrophic epidermolysis 
bullosa patient. 
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[9]. integrin is the unique integrin, because the other integrins normally attach to actin, 
while  integrin attaches to intermediate filament, keratin [10]. integrin attaches to 
intermediate filament by plectin [10]. BP180 tethers keratin through the interaction with 
BP230 in the cytoplasm [10]. Both BP180 and BP230 are the target of major subepidermal 
autoimmune bullous disease, bullous pemphigoid [11]. Basement membrane is mainly 
composed of collagen IV [12]. Laminin-332 and collagen VII adhere to collagen IV [7]. All 
these components are molecules which are affected by EB patients [1]. 
3. JEB (Figure 2) 
The manner of inheritance in JEB patients is autosomal recessive [1]. As mentioned above, 
skin separation in JEB occurs in the lamina lucida [1]. Three subtypes of JEB exsist, Herlitz 
JEB, non-Herlitz JEB and JEB with pyloric atresia [1]. Herlitz JEB is fatal subtype of JEB [1]. 
Most affected patients die from systemic infection through severe erosion on virtually entire 
skin [1]. Herlitz JEB is caused by homozygous or compound heterozygous premature 
termination codon (PTC) mutation of laminin-332 [13,14]. Non-Herlitz JEB is much milder 
than Herlitz JEB [1]. Either missense mutation of laminin-332 or mutation of BP180 is found 
in non-Herlitz JEB patients [15-17]. JEB with pyloric atresia is possibly life-threatening 
subtype, similar to Herlitz JEB [1]. However, JEB with pyloric atresia patients occasionally 
show non-life-threatening phenotype like non-Herlitz JEB patients [1]. Mutations in  or  
integrin genes are found in JEB with pyloric atresia patients [1,18,19]. PTC mutations of 
or  integrin genes are found in severe JEB with pyloric atresia patients, whereas 
missense mutations of these integrin genes are found in milder subtype of JEB with pyloric 
atresia patients [1,20]. 
4. DEB 
Tissue separation of DEB occurs in the dermis [1]. Clinically, DEB patients show blistering of 
the skin in the large area along with scarring and milia formation [15]. Two fashions of 
inheritance are known in DEB, autosomal dominant and autosomal recessive [15]. DEB is 
known to be caused by mutations in collagen VII gene. More than 300 mutations are 
reported in DEB [15]. Glycine substitution mutation in one allele of gene encoding the 
collagenous domain of collagen VII is known to be strongly associated with DEB [21]. Such 
mutation probably has a dominant negative effect on collagen VII formation or assembly 
[15]. In the severest form of DEB, Hallopeau-Siemens recessive DEB, PTC mutation on both 
alleles of gene encoding collagen VII is found [22]. In the mildest form of recessive DEB, 
non-Hallopeau-Siemens recessive DEB, PTC mutations in one allele, missense or in-frame 
mutations are found in the genes encoding collagen VII [23]. 
5. Diagnosis 
The hallmark of the diagnosis of EB is made by DNA-based mutational analysis [1]. 
However, it is required to minimize the effort to specify the possible affected gene through 
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history taking, clinical assessment, histopathological study, immunomapping study and 
electronmicroscopic study [1]. Using these methods, we can categorize the disease type of 
patients into at least three forms, EBS, JEB and DEB [1]. Histopathology or 
electronmicroscopy samples should be taken after gentle rubbing on non-blistered skin, in 
order not to misdiagnose the location of blister by degeneration of the affected skin [1]. 
Immunomapping study using anti-K5, K14,  integrin,  integrin, BP180, plectin, laminin-
332 or collagen VII antibody is quite useful to diagnose EB, if the affected mutation locates 
on the portion of epitope targeted by these antibodies [1]. In addition, immunohistochemical 
study using anti-collagen IV antibody is also useful to assess the portion of the split [1]. In 
EBS or JEB sample, positive staining of collagen IV is found at the floor of the blister, 
whereas in DEB sample, that is found at the roof of the blister [1]. After these careful 
assessments, DNA-based diagnoses are performed [1]. 
6. Treatment 
Treatment of EB is mainly symptomatic one. Most important issue is to prevent local 
infection, including Staphylococcus aureus, Streptococcus pyogenes and Psudomonas 
aeruginosa. If we fail to control local infection, subsequent sepsis occurs with high 
possibility. In order to prevent such local infection, semiocclusive nonadherent dressings 
with or without topical antibiotics is selected for the treatment of EB. In addition, as 
esophageal ocular and oral complications are also found in EB patients, clinical 
care for erosions in these organs are also required to prevent local infection and resultant 
sepsis.  
Allogeneic skin grafts, in which cells do not derived from patients, were tried for EB 
patients. These allografts were rejected but could produce cytokines to facilitate the wound 
healing and re-epithelization process. 
7. Ongoing therapies 
As symptomatic therapy is only available for EB, future gene-targeted therapy is highly 
expected and is being considered. To attempt to do so, cell-based therapies using fibroblasts 
and allogeneic bone marrow transplantation are the potential options. As the experimental 
level, such therapies were successful for JEB and DEB. Collgen VII is known to be 
synthesized mainly by keratinocytes and to a lesser extent by fibroblasts [19]. As fibroblasts 
are easy to culture and easy to get transfected by external genes than keratinocytes, cell-
based therapies using fibroblasts are selected for the possible gene therapy for DEB [1]. In 
fact, Goto et al. successfully restores collagen VII by skin collagen VII gene transfected 
fibroblast introduction [24]. In addition, clinical study for five patients using this technique 
was already successful without any adverse effects [25]. Cultured patient keratinocytes 
transfected with laminin 3 gene through retroviral technique were successfully transferred 
and healed blister formation in one patient. Collagen VII protein therapy was also 
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introduced and was successful in an in vivo model. The missing or defective protein, 
synthesized by in vitro recombinant methods, is introduced to blistered skin. Successful 
treatment was already obtained in case of collagen VII [26,27]. 
Allogeneic bone marrow transplantation is the other option. In EB patients, basal 
keratinocytes produce defective gene product of BMZ [1]. It is known that, bone marrow 
cells have a potential to differentiate into epidermal keratinocytes [17]. Therefore, allogeneic 
bone marrow transplantation can correct such defective BMZ components. As an 
experimental level, Chino et al. was successful in correcting ameliorated collagen VII in 
collagen VII knock out mice by allogeneic bone marrow transplantation [28]. Moreover, 
clinical trial using this technology and cord blood transplantation were already started and 
were obtained successful results [1]. 
8. Conclusion 
EB is a life-threatening and life-long disease with only symptomatic treatments, thus far. 
However, cell-based gene-targeting therapy is on the way to be successful. 
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